| abstract |
The present invention provides a compound of formula (I): or an enantiomer, mixture of enantiomers or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds to treat diseases or disorders mediated by mixed lineage leukemia 1 (MLL). |